Literature DB >> 25377534

Should non-cardiovascular mortality be considered in the SCORE model? Findings from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort.

Biniyam G Demissei1, Douwe Postmus, Mattia A Valente, Pim van der Harst, Wijk H van Gilst, Edwin R Van den Heuvel, Hans L Hillege.   

Abstract

Competing non-cardiovascular related deaths were not accounted for in the Systematic COronary Risk Evaluation (SCORE) model. In this study we assessed the impact of non-cardiovascular related deaths on the prognostic performance and yield of the SCORE model. 5,752 participants from the Prevention of Renal and Vascular End stage Disease cohort aged 40 years and older who were free of atherosclerotic cardiovascular disease (CVD) at baseline were included. A cause-specific hazards (CSH) CVD-related mortality prediction model that accounted for non-CVD-related deaths was developed. The prognostic performance of this model was then compared with a refitted SCORE model. During a median follow-up period of 12.5 years, 139 CVD and 495 non-CVD-related deaths were reported. Discriminatory performance was comparable between the models (C-index = 0.64). The models showed good calibration although the CSH model underestimated risk in the highest decile while the refitted SCORE model showed overestimation. The CSH model classified more non-events into the low risk group compared to the refitted SCORE model (n = 51), yet it was accompanied by a misclassification of six events into the low risk group. The refitted SCORE model classified more individuals as high risk. However, the potential overtreatment that may result from utilizing the refitted SCORE model, when compared with the CSH model, still falls within acceptable limits. Our findings do not support the incorporation of non-cardiovascular mortality into the estimation of total cardiovascular risk in the SCORE model.

Entities:  

Mesh:

Year:  2014        PMID: 25377534     DOI: 10.1007/s10654-014-9967-3

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  26 in total

Review 1.  Risk prediction models: II. External validation, model updating, and impact assessment.

Authors:  Karel G M Moons; Andre Pascal Kengne; Diederick E Grobbee; Patrick Royston; Yvonne Vergouwe; Douglas G Altman; Mark Woodward
Journal:  Heart       Date:  2012-03-07       Impact factor: 5.994

2.  Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.

Authors:  Rod Jackson; Carlene M M Lawes; Derrick A Bennett; Richard J Milne; Anthony Rodgers
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

3.  Prognostic models with competing risks: methods and application to coronary risk prediction.

Authors:  Marcel Wolbers; Michael T Koller; Jacqueline C M Witteman; Ewout W Steyerberg
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

Review 4.  Statins in the primary prevention of cardiovascular disease.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2013-06-04       Impact factor: 32.419

5.  N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population.

Authors:  Gerard C M Linssen; Stephan J L Bakker; Adriaan A Voors; Ron T Gansevoort; Hans L Hillege; Paul E de Jong; Dirk J van Veldhuisen; Rijk O B Gans; Dick de Zeeuw
Journal:  Eur Heart J       Date:  2009-10-23       Impact factor: 29.983

Review 6.  Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide.

Authors:  Maarten J G Leening; Moniek M Vedder; Jacqueline C M Witteman; Michael J Pencina; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2014-01-21       Impact factor: 25.391

7.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

8.  Concordance for prognostic models with competing risks.

Authors:  Marcel Wolbers; Paul Blanche; Michael T Koller; Jacqueline C M Witteman; Thomas A Gerds
Journal:  Biostatistics       Date:  2014-02-02       Impact factor: 5.899

9.  Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

Authors:  Edward J Mills; Beth Rachlis; Ping Wu; Philip J Devereaux; Paul Arora; Dan Perri
Journal:  J Am Coll Cardiol       Date:  2008-11-25       Impact factor: 24.094

10.  Competing risks and the clinical community: irrelevance or ignorance?

Authors:  Michael T Koller; Heike Raatz; Ewout W Steyerberg; Marcel Wolbers
Journal:  Stat Med       Date:  2011-09-23       Impact factor: 2.373

View more
  2 in total

1.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

2.  Predicting Risk of Atherosclerotic Cardiovascular Disease Using Pooled Cohort Equations in Older Adults With Frailty, Multimorbidity, and Competing Risks.

Authors:  Quoc Dinh Nguyen; Michelle C Odden; Carmen A Peralta; Dae Hyun Kim
Journal:  J Am Heart Assoc       Date:  2020-09-02       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.